Shares of Protagonist Therapeutics PTGX have jumped 64% over the past six months compared with the industry’s 4.5% growth.

Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...

Protagonist Therapeutics (PTGX) shares rallied 7.1% in the last trading session to close at $140.85. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Protagonist Therapeutics (PTGX) has been in focus after two key milestones: the FDA approval and U.S. launch of Icotyde for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Rusfertide, a hepcidin-mimetic peptide, reduces excess red blood cell production in polycythemia vera, addressing complications like blood clots and fatigue. The FDA granted rusfertide breakthrough ...

The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and ...

Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2 ...

After a very large three year return, Protagonist Therapeutics now faces a valuation debate, with the stock’s strong share ...